# CG Oncology (CGON) — Overview

CGON · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/cgon

## Price

Last close $61.86 on Oct 15, 2026. 52-week range $37.37 – $80.68.

## Company profile

CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.

## Financials

| Metric | Value |
| --- | --- |
| Revenue (trailing twelve months) | $6.2M |
| Revenue (quarter) | $1.2M |
| Revenue growth (year over year) | 0.00% |
| Gross profit (trailing twelve months) | −$5.3M |
| Gross margin | -85.20% |
| Net income (trailing twelve months) | −$224.4M |
| Net income (quarter) | −$79.1M |
| Net income growth (year over year) | -90.84% |
| Net margin | -3602.68% |
| Return on equity | -26.41% |
| EPS (trailing twelve months) | −$2.69 |
| Book value per share | $11.65 |
| P/E (trailing twelve months) | — |
| Price to book | 5.3 |
| Debt to assets | 5.21% |
| Payout ratio | 0.00% |
| Dividend yield | 0.00% |

## Frequently Asked Questions

### Is CG Oncology (CGON) profitable?

No. CG Oncology reported a net loss of $224.4M over the trailing twelve months.

### How much revenue does CG Oncology (CGON) make?

CG Oncology generated $6.2M in revenue over the trailing twelve months.

### How do I buy stock in CG Oncology (CGON)?

CGON trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at [Light Horse Dashboard](https://portal.lighthorse.io), the trading API, or an [AI agent connected over MCP](/instructions/ai/claude). The trade panel on this page places the order once you are signed in.

---

Quotes and charts are not real-time and must not be relied on for trade decisions or valuation.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).